IRVINE, CA / ACCESSWIRE / March 24, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against DaVita Inc. (“DaVita” or the “Company”) (NYSE: DVA). Investors, who purchased or otherwise acquired shares between August 5, 2015 and October 21, 2016, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the April 3, 2017 lead plaintiff motion deadline.

If you purchased shares of DaVita during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

On January 6, 2017, the Wall Street Journal announced DaVita had received subpoenas from federal prosecutors for “the production of information related to charitable premium assistance” concerning the Company’s relationship with the American Kidney Fund, a charity that offers financial help for patients undergoing kidney dialysis. When this information was released to the public, the value of DaVita stock fell, causing investors harm.

If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 458104

NEW YORK, NY / ACCESSWIRE / March 24, 2017 / OneSoft Solutions Inc. (TSX-V: OSS.V), a developer of revolutionary SaaS software solutions designed to assist oil and gas pipeline companies to reduce or eliminate pipeline failures, will be presenting at this year’s MicroCap Conference on April 4th in New York City.

The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It provides an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other investors.

The MicroCap Conference, which caters specifically to portfolio managers, analysts and private investors, will take place in New York City at the Essex House on April 4th. Registration will begin on Tuesday, April 4th, at 7:00AM, and the event ends with a reception in the evening. The day’s events will include company presentations, one-on-one meetings, and opportunities to network with other investors during the conference and following reception.

REGISTRATION FOR INVESTORS

To register, please go to our website (www.microcapconf.com) and click “Register.”

PARTICIPATING COMPANIES

For our most updated list of companies, please go to our website (http://microcapconf.com/conferences/new-york-2017/).

MARQUEE SPONSORS

The Special Equities Group

Maxim Group

News Compliments of ACCESSWIRE.

FOR MORE INFORMATION

Please visit: www.microcapconf.com.

Or contact Tony Yu at
tony@microcapconf.com.

SOURCE: OneSoft Solutions Inc.

ReleaseID: 458103

NEW YORK, NY / ACCESSWIRE / March 24, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Roadrunner Transportation Systems, Inc. (“Roadrunner” or the “Company”) (NYSE: RRTS) and certain of its officers, on behalf of a class who purchased Roadrunner securities between May 8, 2014, and January 30, 2017, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/rrts.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Roadrunner lacked effective internal controls over financial reporting; (2) Roadrunner’s financial statements since early 2014 exaggerated the estimated results of operations; (3) Roadrunner’s financial statements contained errors relating to unrecorded expenses from unreconciled balance sheet accounts, including cash, driver and other receivables, and linehaul and other driver payables; and (4) consequently, Roadrunner’s financial statements since early 2014 were not reliable.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/rrts, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Roadrunner, you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 454380

NEW YORK, NY / ACCESSWIRE / March 24, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Psychemedics Corporation (“Psychemedics” or the “Company”) (NASDAQ: PMD) and certain of its officers, on behalf of a class who purchased Psychemedics securities between February 28, 2014 and January 30, 2017, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/pmd.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) through its affiliate, Psychemedics Brasil Exames Toxicologicos Ltda., Psychemedics engaged in anticompetitive conduct to maintain a monopoly over the Brazilian market in violation of the law; (2) effectively, Psychemedics lacked effective internal controls over financial reporting; and (3) consequently, Psychemedics’ public statements were materially false and misleading at all relevant times.

On January 31, 2017, it was revealed that Psychemedics Brasil Exames Toxicologicos Ltda., Psychemedics’ local representative in Brazil, was ordered to compensate Omega Laboratories, Inc. USA for losses caused by anticompetitive practices used for “preventing other companies from accessing (the) market.” Following this news, Psychemedics stock dropped during intra-trading on January 31, 2017.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: www.bgandg.com/pmd, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Psychemedics, you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 454542

NEW YORK, NY / ACCESSWIRE / March 24, 2017 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Babcock & Wilcox Enterprises, Inc. (“Babcock & Wilcox” or the “Company”) (NYSE: BW) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased Babcock & Wilcox securities between July 1, 2015, and February 28, 2017, both dates inclusive (the “Class Period”). Investors are encouraged to learn more about this case by visiting the firm’s site: http://www.bgandg.com/bw.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The complaint alleges that throughout the class period, defendants made false and misleading statements and/or failed to disclose that: (1) Babcock & Wilcox’s Renewable business had productivity and scheduling issues; (2) these hidden problems decreased profit margins and worsened financial performance; (3) Babcock & Wilcox’s Renewable business suffered from problematic on-site project management and a lack of resources in engineering and project management groups, which resulted in overly aggressive project bidding, project delays, and engineering errors; (4) Babcock & Wilcox lacked adequate project management processes in its Renewable business, which negatively impacted performance on key projects from bidding through execution; (5) consequently, defendants’ statements about it outlook and expected financial performance were false and misleading and lack a reasonable basis when made.

On March 1, 2017, Babcock & Wilcox revealed its fourth quarter and full year 2016 financial results, which were below analyst projections, reporting “fourth quarter 2016 revenues of $380.0 million, a decrease of $122.7 million, or 24.4%, compared to the fourth quarter of 2015. GAAP earnings per share for the fourth quarter of 2016 were a loss of $1.47 compared to a loss per share of $0.10 for the fourth quarter of 2015.” Following this news, Babcock & Wilcox stock dropped over 39% during intraday trading on March 1, 2017.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/bw, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. You have until May 2, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 456939

NEW YORK, NY / ACCESSWIRE / March 24, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Stemline Therapeutics, Inc. (“Stemline” or the “Company”) (NASDAQ: STML) and certain of its officers, on behalf of a class who purchased Stemline securities between January 20, 2017 and February 1, 2017, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/stml.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose that: (1) a patient had died in the BPDCN Trial from capilliary leak syndrome immediately prior to Stemline’s stock offering despite constantly affirming that capillary leak syndrome was a potential side-effect of SL-401; and (2) SL-401’s safety profile was not predictable and manageable over increasing treatment duration, drug exposure, and patient experience as represented by the Defendants.

On January 19, 2017, Stemline announced its proposed public offering of common stock and on the next day, January 20, 2017, Stemline set the pricing of the public offering of 4.5 million shares at $10.00 per share, with projected gross proceeds of $45 million. On February 2, 2017, TheStreet narrated that on January 18, 2017, a cancer patient in a clinical trial died from a severe side effect tied to Stemline’s drug SL-401 and this information was not disclosed to investors who bought into Stemline’s public offering. Following this news, Stemline stock dropped during intraday trading on February 2, 2017.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/stml, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Stemline, you have until April 4, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 454387

NEW YORK, NY / ACCESSWIRE / March 24, 2017 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Patriot National (“Patriot” or the “Company”) (NYSE: PN) and certain of its officers, on behalf of shareholders who purchased Patriot securities between August 15, 2016 and March 3, 2017, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/pn.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements and failed to disclose that: (1) Patriot National special committee was beholden to CEO, Steve Mariano; (2) therefore, the special committee was operating for the benefit of Mariano and not Patriot National or its shareholders; (3) the special committee did not independently assess the merits of the Ebix transaction; (4) the special committee was not exploring strategic alternatives in order to maximize shareholder value; and (5) consequently, defendants’ statements about Patriot National’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/pn, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Patriot, you have until May 15, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 457863

NEW YORK, NY / ACCESSWIRE / March 24, 2017 / IDW Media Holdings (OTCQX: IDWM) will be presenting at this year’s MicroCap Conference on April 4th in New York City.

CONFERENCE OVERVIEW AND STRUCTURE

The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other investors.

The MicroCap Conference will take place in New York City at the Essex House on April 4th. Registration will begin on Tuesday, April 4th, at 7:00AM, and the event ends with a reception in the evening. The day will be jam-packed with company presentations, one-on-one meetings, good food, and plenty of time to network with other investors over drinks at the reception. This event does not allow service providers – only portfolio managers, analysts, and private investors.

REGISTRATION FOR INVESTORS

To register, please go to our website (www.microcapconf.com) and click “Register.”

PARTICIPATING COMPANIES

For our most updated list of companies, please go to our website (http://microcapconf.com/conferences/new-york-2017/).

MARQUEE SPONSORS

The Special Equities Group
Maxim Group

News Compliments of ACCESSWIRE.

ABOUT IDW MEDIA HOLDINGS, INC.

IDW Media Holdings, Inc. (OTCQX: IDWM) is a fully integrated media company, which includes IDW Publishing, IDW Entertainment, and CTM Media Group.

IDW Publishing’s comic book and graphic novel catalog includes some of the world’s most popular entertainment brands, including Transformers, My Little Pony, Star Trek, Teenage Mutant Ninja Turtles, Ghostbusters, and Disney’s classic characters. At IDW’s core is its commitment to creator-owned comics, including 30 Days of Night, Locke & Key, Wormwood, Ragnarök, V-Wars, and Archangel. The acclaimed and award-winning imprints, Top Shelf, The Library of American Comics, Yoe! Books and Artist Editions, showcasing the greatest original art ever published in American comic books.

IDW Games’ diverse line-up includes the international phenomenon, Machi Koro, as well as hit licensed games, such as X-Files, Back to the Future, The Godfather, and Teenage Mutant Ninja Turtles.

IDW Entertainment currently serves as the worldwide distributor of SyFy’s Wynonna Earp and is producing BBC America’s Dirk Gently’s Holistic Detective Agency, based on the beloved novels by Douglas Adams and starring Elijah Wood and Sam Barnett. Both series have been renewed for second seasons, with anticipated premieres in 2017. IDW Entertainment has strategic alliances with major talent, including the just announced Jonathan Kellerman best-selling series of books, featuring Alex Delaware, and The Devil, with Grey’s Anatomy’s Ellen Pompeo. In addition, Locke & Key, created by The New York Times Bestseller, Joe Hill, is currently in development for a television series.

CTM Media Group is one of North America’s largest distributors of tourism information, distributing over 100 million brochures last year.

CONTACT INFORMATION

Les Rozner
lrozner@idwmediaholdings.com
(203) 716-8376

FOR MORE INFORMATION

Please visit: www.microcapconf.com.

Or, contact Tony Yu at tony@microcapconf.com

SOURCE: IDW Media Holdings, Inc.

ReleaseID: 458102

The Goal of the Dark Comedy and Mystery is to Entertain and Educate Audiences, While Doing Away with Social Stigmas about Anxiety Disorders

LOS ANGELES, CA / ACCESSWIRE / March 24, 2017 / Director Julia Cowle is pleased to announce the upcoming release of her film, Winfield Historical Times…And Other Oddities.

To watch a short video about the upcoming movie, and to learn more about Cowle and the rest of the talented team that is working on this innovative film, please check out https://goo.gl/AR4uAt at any time.

As a spokesperson for the dark comedy/mystery movie noted, Winfield Historical Times…And Other Oddities is a NYU thesis film that will shed much-needed light on the rise of anxiety disorder. Cowle’s goal is to do away with the social stigmas that surround the condition, while also entertaining audiences. The film will utilize stop motion and feature elaborately designed scenes and sets.

The film tells the story of a young girl named Chloe who lives a rather typical suburban life in a small cul-de-sac filled with colorful characters. Chloe suffers from anxiety and, because of it, becomes a pariah in her close knit, but well intentioned, community.

One morning, Chloe agrees to find the thief who is stealing Mr. Gladstein’s newspapers. In an effort to find the paper bandit, Chloe begins to track her neighbors’ activities and soon learns that behind the lovely front doors in her neighborhood, things are not what they appear to be.

“As Chloe gets closer and closer to the truth of the disappearing newspaper, Chloe also learns more about herself,” the spokesperson noted, adding that a neighborhood block party that is meant to unite the community brings the film to a surprising and comical conclusion.

In order to help pay for the production expenses associated with bringing Winfield Historical Times…And Other Oddities to life, Cowle recently launched a fundraiser on Indiegogo. There, she and her team hope to raise $15,000 through crowdfunding.

“We want our film to be enjoyed and noticed by as wide an audience as possible, therefore we intend to distribute primarily through the independent festival circuit,” Cowle noted, adding that after the festival circuit run is finished, the film will be uploaded to Vimeo for more widespread general access.

About Winfield Historical Times…And Other Oddities:

Winfield Historical Times…And Other Oddities is an NYU Thesis Film that sheds light on the rise of anxiety disorder, dismantling all social stigmas surrounding it. The dark comedy/mystery tells the story about a young girl named Chloe who sets out to discover who is stealing a neighbor’s newspapers. For more information, please visit https://goo.gl/AR4uAt.

Contact:

Tamara Copeland
admin@rocketfactor.com
(949) 555-2861

SOURCE: Winfield Historical Times…And Other Oddities

ReleaseID: 458099

NEW YORK, NY / ACCESSWIRE / March 24, 2017 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against NantHealth, Inc. (“NantHealth” or the “Company”) (NASDAQ: NH) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased NantHealth securities (1) pursuant and/or traceable to NantHealth’s false and misleading Registration Statement and Prospectus, issued in connection with the Company’s initial public offering on or about June 2, 2016 (the “IPO” or the “Offering”); and/or (2) on the open market between June 2, 2016 and March 3, 2017, both dates inclusive (the “Class Period”). Investors are encouraged to learn more about this case by visiting the firm’s site: http://www.bgandg.com/nh.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

In September 2014, NantHealth’s founder and Chief Executive Officer (“CEO”), Defendant Patrick Soon-Shiong, publicized a $12 million donation to the University of Utah for an initiative to find genetic clues for the cause of diseases, including several cancers and amyotrophic lateral sclerosis. The donation came from three different tax-exempt entities controlled by Soon-Shiong: $9 million from two private foundations, and the remaining $3 million from the NantHealth Foundation, a medical research organization.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Defendant Soon-Shiong focused business to NantHealth through his donation to the University of Utah, pursuant to the contractual terms of which the university was effectively required to spend $10 million on genetics analysis performed by the Company; (2) as a result, the number of test orders that NantHealth reported to investors was artificially inflated; (3) the contracts governing Soon-Shiong’s donation to the university violated federal tax law; and (4) consequently, NantHealth’s public statements were materially false and misleading at all relevant times.

On March 6, 2017, STAT, a news source reported that NantHealth founder, Patrick Soon-Shiong, had donated $12 million to the University of Utah from three different tax-exempt entities he controlled under a contract that required the University to funnel most of that money into NantHealth. STAT also alleged that this scheme allowed NantHealth to inflate the number of test orders it reported to investors. Following this news, NantHealth stock dropped $1.67 per share, or 23.29%, to close at $5.50 on March 6, 2017.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/nh, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. You have until May 8, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 456934